A
3.23
-0.28 (-7.98%)
Penutupan Terdahulu | 3.51 |
Buka | 3.41 |
Jumlah Dagangan | 1,499,099 |
Purata Dagangan (3B) | 928,462 |
Modal Pasaran | 618,480,384 |
Harga / Jualan (P/S) | 97.15 |
Harga / Buku (P/B) | 6.35 |
Julat 52 Minggu | |
Tarikh Pendapatan | 30 Apr 2025 - 5 May 2025 |
Margin Operasi (TTM) | -995.43% |
EPS Cair (TTM) | -0.380 |
Pertumbuhan Hasil Suku Tahunan (YOY) | -26.60% |
Jumlah Hutang/Ekuiti (D/E MRQ) | 6.28% |
Nisbah Semasa (MRQ) | 8.15 |
Aliran Tunai Operasi (OCF TTM) | -64.85 M |
Aliran Tunai Bebas Leveraj (LFCF TTM) | -41.56 M |
Pulangan Atas Aset (ROA TTM) | -33.36% |
Pulangan Atas Ekuiti (ROE TTM) | -68.76% |
Arah Aliran Pasaran
Jangka Pendek | Jangka Sederhana | ||
Industri | Biotechnology (US) | Bercampur | Bercampur |
Biotechnology (Global) | Bercampur | Bercampur | |
Stok | Arbutus Biopharma Corporation | Bercampur | Menaik |
AISkor Stockmoo
2.4
Konsensus Penganalisis | 2.5 |
Aktiviti Orang Dalam | NA |
Volatiliti Harga | 2.0 |
Purata Bergerak Teknikal | 1.0 |
Osilator Teknikal | 4.0 |
Purata | 2.38 |
Arbutus Biopharma Corp is a biopharmaceutical company. The company discovers, develops, and commercializes cures for patients suffering from Hepatitis B infection. The company is focused on developing a portfolio of drug candidates with multiple mechanisms of action and is also involved in licensing Lipid nanoparticle technology. |
|
Sektor | Healthcare |
Industri | Biotechnology |
Gaya Pelaburan | Small Value |
% Dimiliki oleh Orang Dalam | 22.03% |
% Dimiliki oleh Institusi | 54.77% |
Pemilikan
Nama | Tarikh | Syer Dipegang |
---|---|---|
Blackbarn Capital Partners Lp | 31 Dec 2024 | 2,341,871 |
Julat 52 Minggu | ||
Julat Harga Sasaran | ||
Tinggi | 5.00 (Chardan Capital, 54.80%) | Beli |
5.00 (HC Wainwright & Co., 54.80%) | Beli | |
Median | 5.00 (54.80%) | |
Purata | 5.00 (54.80%) | |
Jumlah | 2 Beli | |
Harga Purata @ Panggilan | 3.36 |
Syarikat | Tarikh | Harga Sasaran | Panggilan | Harga @ Panggilan |
---|---|---|---|---|
Chardan Capital | 28 Mar 2025 | 5.00 (54.80%) | Beli | 3.50 |
HC Wainwright & Co. | 21 Jan 2025 | 5.00 (54.80%) | Beli | 3.21 |
Tiada data dalam julat masa ini.
Tarikh | Jenis | Butiran |
---|---|---|
27 Mar 2025 | Pengumuman | Arbutus Reports Fourth Quarter and Year End 2024 Financial Results and Provides Corporate Update |
03 Mar 2025 | Pengumuman | Genevant Sciences and Arbutus Biopharma Initiate International Patent Infringement Enforcement Actions Against Moderna |
13 Jan 2025 | Pengumuman | Arbutus Provides 2025 Corporate and Financial Update |
Tahap sokongan, rintangan dan garis aliran yang dibentangkan telah dihasilkan oleh model kecerdasan buatan (AI) dan harus ditafsirkan dengan berhati-hati.
Portfolio
Keuntungan Nyata | - |
Keuntungan Tidak Nyata | - |
Dividen Diterima 2025 | - |
Jumlah Untung | - |
Pulangan Purata | - |
Kuantiti (Beli) | - |
Purata Harga (Beli) | - |
Kuantiti (Jual) | - |
Purata Harga (Jual) | - |